| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 8, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage and metastatic status in high-potential indications, including lung, ovarian and endometrial cancers Findings support potential of PTK7 as a pan-tumor target, reinforcing Whitehawk's development of PTK7-directed ADC HWK-007 MORRISTOWN, N.J., Oct. 24, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today prese
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial
MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.A live webcast of the fireside chat events can be
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)